New Zealand's legal and institutional requirements prohibit the provision of patient-level clinical information in order to protect the privacy of natural persons. Researchers who meet the criteria for access to confidential data may approach the Ministry of Health (<data-enquiries@moh.govt.nz>) who are the custodians of national clinical datasets and whose data we used. Their current data access policy is described at <https://www.health.govt.nz/publication/current-data-access-policy>. The authors are willing to provide the data specification and analysis code.

Introduction {#sec007}
============

Diverticular disease of the intestine (DDI) is a common long term condition with significant impacts on morbidity\[[@pone.0219818.ref001]--[@pone.0219818.ref004]\] and healthcare expenditure.\[[@pone.0219818.ref005], [@pone.0219818.ref006]\] Thorough understanding of the epidemiology and current management patterns is important for optimal management,\[[@pone.0219818.ref007], [@pone.0219818.ref008]\] although research about DDI--its epidemiology and treatment--almost entirely uses hospitalisation data.\[[@pone.0219818.ref009]--[@pone.0219818.ref012]\] The frequency that DDI is managed in primary care is largely unknown. In the Netherlands, most patients presenting to primary care with symptoms suggestive of DDI are managed in the community; just one in eight patients is hospitalised.\[[@pone.0219818.ref013]\] In Italy, a general practice research database shows DDI incidence across all ages as about 2.6 per 1000, of whom 27% had been hospitalised since, but just 3.4% were admitted for DDI.\[[@pone.0219818.ref014]\] Variations in current practice and lack of consensus with clinical guidelines indicate the potential for new evidence to enable improvements in care and advice.\[[@pone.0219818.ref014]--[@pone.0219818.ref017]\] Not the least of these variations concerns use of antibiotics--when is their use necessary, which medications to choose, and can their use be avoided in order to reduce antibiotic resistance?\[[@pone.0219818.ref018]\] Until quite recently, oral antibiotics (e.g. penicillin) have been the mainstay of non-surgical DDI management.\[[@pone.0219818.ref019]\] Therefore, one potential approach to estimate the impact of DDI in the community is to examine and compare the patterns of antibiotic use between people with a history of DDI against matched counterparts without the disease. Antibiotic use that exceeds that of population controls has potential to indicate the extent DDI is managed in primary care. Using this approach, this study aims to use any excess in antibiotic dispensing to estimate how often DDI is managed in primary care.

Methods {#sec008}
=======

The University of Auckland Human Participants Ethics Committee approved the study (Ref. 016560).

Study design and data sources {#sec009}
-----------------------------

In New Zealand (NZ), Ministry of Health (MoH) collects details of publicly-funded hospitalisations, subsided prescribed medicines and deaths, visits and subsidy claims in primary care but does not collect clinical information. In this population-based study we assembled relevant antibiotic dispensing records for a whole population, comparing dispensing for people with a prior hospital-based DDI diagnosis with that of their counterparts without a DDI history. Unlike some other countries, in New Zealand antibiotics are available only when prescribed by a registered medical practitioner and dispensed by a qualified and registered pharmacist.

Three linked national health databases are employed: the National Health Index (NHI), the National Minimum Dataset (NMDS), and the Pharmaceutical database (PHARMS). The NHI contains demographic and identifying information for all who use health and disability support services in the health system, and covers at least 95% of the NZ population.\[[@pone.0219818.ref020]\] The NMDS collects public and private hospital discharge data for inpatients and day patients (excluding those presenting to emergency departments or if discharged within 3 hours).\[[@pone.0219818.ref021]\] Since July 1999 (throughout this study), hospital diagnoses have been coding using the ICD-10-AM system.\[[@pone.0219818.ref022]\] Each hospitalisation is also classified by clinical coders as acute or non-acute (booked or waitlisted) using an "admission type" code. The PHARMS database collects community-based dispensing data for prescribed and subsidised medications.\[[@pone.0219818.ref023]\] All three databases are indexed with an encrypted patient identifier. Data from all sources were extracted for each eligible resident and merged individually.

Selection and classification of participants {#sec010}
--------------------------------------------

Study participants were selected from the NHI database if meeting the following criteria: were citizens or residents of NZ; born between 1900 and 1986; date of last contact with the health service--hospitalisation, an outpatient visit, a delivery (as mother), a death, a medication dispensed from a community pharmacy, a primary care consultation or enrolment, a contact with a mental health service, a vaccination, a laboratory test, or a medical subsidy--was after July 1999 and at that time they gave a NZ address; there was no record of DDI prior to 1 July 2007; and there was no record of death before June 2002. Almost all residents aged 30+ years are therefore included, except those with missing demographic data for gender, year of birth or region of current residence, or with clear errors or outliers, e.g. exceeding 108 antibiotics dispensed during the 9 year period (more than once a month), or with prior DDI ([Fig 1](#pone.0219818.g001){ref-type="fig"}).

![Flow chart of included people with diverticular disease of the intestine and matched people without diverticular disease.](pone.0219818.g001){#pone.0219818.g001}

From the NMDS database, hospital admissions during July 2002-June 2016 with DDI identified using any of the ICD-10-AM codes K57.0--K57.9 (whether incident/recurrent, uncomplicated/not, primary/other diagnosis or colonic/otherwise) were regarded as having DDI\[[@pone.0219818.ref024]\]. The first DDI admission after 30 years of age was regarded as the "index" admission, classed as acute/non-acute using a routine clinical code, and the date of that admission taken as the index date.

Non-DDI participants were randomly matched 10:1 with DDI participants of the same birth year, gender and self-identified ethnic group, taking the admission date of their matched case as their index date.

Use of prescribed antibiotics {#sec011}
-----------------------------

From the PHARMS database were extracted records of relevant government-subsidised oral antibiotics dispensed by community pharmacies 1 July 2007--30 June 2016 ([Table 1](#pone.0219818.t001){ref-type="table"}). Using published articles and in consultation with NZ medical practitioners, we pre-specified a list of DDI-relevant antibiotics available from community pharmacies under NZ's pharmaceutical schedule.\[[@pone.0219818.ref025]--[@pone.0219818.ref028]\] The dispensing database was searched for all participants to extract the chemical name, formulation name and date dispensed. Since it is extremely rare in NZ for government-funded medicines to be paid for entirely privately, dispensing data will be virtually complete.

10.1371/journal.pone.0219818.t001

###### Number of days on which chosen antibiotics were dispensed (for any purpose) to participants with a history of diverticular disease of the intestine (n = 51,059) and matched participants (n = 510 581), over the 9-year period from July 2007 to June 2016.

![](pone.0219818.t001){#pone.0219818.t001g}

  Chemical name                                         Chemical code   Anatomical Therapeutic Chemical (ATC) classification codes   Courses dispensed   
  ----------------------------------------------------- --------------- ------------------------------------------------------------ ------------------- -------
  **Present in dispensing database**:                                                                                                                    
   Amoxicillin with clavulanic acid                     1070            J01CR02                                                      928 592             36.1
   Amoxicillin without clavulanic acid                  1072            J01CA04, QG51AX03                                            821 931             32.0
   Cefaclor monohydrate                                 1228            J01DC04                                                      277 689             10.8
   Ciprofloxacin                                        2819            J01MA02, S01AE03, S02AA15, S03AA07                           208 227             8.1
   Co-trimoxazole                                       1361            J01EE01                                                      150 361             5.9
   Metronidazole                                        1820            A01AB17, D06BX01, G01AF01, J01XD01, P01AB01, QP51AA01        108 324             4.2
   Cefalexin                                            1234            J01DB01, QJ51DB01                                            37 418              1.5
   Clindamycin                                          1303            J01FF01, D10AF01, G01AA10                                    24 120              0.9
   Ornidazole                                           1906            G01AF06, J01XD03, P01AB03, QP51AA03                          14 409              0.6
   Moxifloxacin                                         3925            J01MA14, S01AE07                                             218                 \<0.1
  Total N of courses of chosen antibiotics dispensed                    2 571 289                                                    100.0               
  **Searched for but not found during study period**:                                                                                                    
   Tinidazole                                           2269            J01XD02, P01AB02, QP51AA02                                                       
   Pivampicillin                                        1998            J01CA02                                                                          
   Pivampicillin hydrochloride                          1999            J01CA02                                                                          
   Levofloxacin                                         3789            J01MA12, S01AE05                                                                 

Note: Other antibiotics (including rifaximin) that are used for DDI in some countries are not listed as they are not funded for diverticular disease and are rarely if ever used in NZ.

Outcomes {#sec012}
--------

Rates of dispensing (for any reason) for specified periods were calculated by dividing the number of days on which antibiotics were dispensed by the total number of days spent alive during the follow-up period. Rates among those with an index date between 2007--2016 were derived.

Analyses {#sec013}
--------

Firstly, for one exemplar 12-month period (July 2012-June 2013) the mean number of antibiotics dispensed was plotted to show annual dispensing rates by age and gender for each of three groups: non-DDI, acute DDI and on-acute DDI.

Secondly, to avoid assuming any statistical distribution across time, 21 separate negative binomial regression models were used to estimate dispensing rates, each for six-months: one centred on the index date, with 10 models prior to, and 10 models after, the index date. A plot shows the pattern of dispensing over time, centred on the index date.

Thirdly, because of the pattern seen in the above results, time was summarised into three periods and dispensing rates modelled within each: *Model A* for the period 2007 to 3 months prior to index date; *Model B* for the period +/-3 months about the index date; and *Model C* for the period 3 months after index date until 2016. Following the advice of Pearce\[[@pone.0219818.ref029]\] "standard" (unconditional) negative binomial regression models were employed, each to estimate three measures of antibiotic use: *dispensing rates* (DR, defined as the mean number of days on which chosen antibiotics were dispensed per 100 person-year), *dispensing rate difference* (DRD, the absolute difference between the rates of the two groups) and *dispensing rate ratio* (DRR, the relative difference between the two groups). Models adjusted for DDI history, year of birth, index year, gender, ethnic group and region.

Fourthly, sensitivity analyses were conducted similar to Models A-C to provide for the matched design by using conditional multivariable negative binomial regressions.

Statistical analyses were performed using SAS v9.4 (SAS Institute Inc., Cary, NC) except the sensitivity analyses that were conducted in Stata v13.0 (StataCorp, College Station, TX). Because of large numbers and multiple testing, two-sided p-values \<0.001 were considered statistically significant.

Results {#sec014}
=======

Participation {#sec015}
-------------

Of the initial 3,564,727 person records initially extracted, 98,623 were excluded, leaving 3,466,104 eligible participants ([Fig 1](#pone.0219818.g001){ref-type="fig"}). During the wider 17-year study period, 84,325 (2.4%) had a hospital diagnosis of DDI; by ICD code, over 97% were colonic.

During the shorter, 9-year period July 2007 to June 2016 (mean duration = 8.6 years), 51,059 (mean age 67.3 years, 23,853 men) received a hospital diagnosis of DDI. DDI was the primary diagnosis code recorded for 20,525 (40.2%); 20,880 (40.9%) were acute index admissions of whom 19,337 (93.6%) were admitted at least overnight. In the remaining 30,179 (59.1%) index admissions, 26,578 (98.3%) received a non-acute colonoscopy. For comparison purposes, 510,581 non-DDI participants were individually-matched to serve as controls.

After the index DDI hospitalisation, 9697 (19.0%) had at least one DDI re-hospitalisation during follow-up (mean 3.6 years).

Antibiotics dispensed {#sec016}
---------------------

Pre-specified oral antibiotics were dispensed by community pharmacies on 2,597,464 occasions, for 47,603 DDI and 383,882 non-DDI participants, over the 9-year period ([Table 1](#pone.0219818.t001){ref-type="table"}). The most commonly dispensed were amoxicillin with/without clavulanic acid, cefaclor monohydrate and ciprofloxacin, together accounting for 87% ([Table 1](#pone.0219818.t001){ref-type="table"}). Over a 12 month period, numbers of community-dispensed antibiotics per person were higher for women than for men, increased with age, and highest for participants with acute DDI ([Fig 2](#pone.0219818.g002){ref-type="fig"}).

![Mean number of days on which antibiotics were dispensed in a single year (July 2012 to June 2013), for those with known prior acute or non-acute hospitalisation for diverticular disease of the intestine (DDI), and those without (non-DDI).\
Notes: Age calculated as at 2012; DDI = hospitalisation with diverticular disease of intestines, acute or non-acute; non-DDI = controls with no hospital record of diverticular disease of intestines.](pone.0219818.g002){#pone.0219818.g002}

[Fig 3](#pone.0219818.g003){ref-type="fig"} illustrates dispensing rates for 6-month periods centred on the index date. During the years prior to the index date, dispensing rates for acute DDI participants rose from a low of about 70 per 100 person-years (/100py) well prior to the index admission, more than tripled during the index period, then dropped to about 120/100py. For non-acute DDI participants, rates rose from 60/100py to under 110/100py by the index admission, then stabilised at about 90/100py thereafter. For non-DDI controls, dispensing rates grew slowly and consistently across the ten years from about 40/100py to almost 60/100py.

![Dispensing rate of selected antibiotics before and after index date for diverticular disease of the intestine participants (n = 51,059: Acute DDI 20,880, non-acute DDI 30,179) and matched non-DDI participants (n = 510 581) during the period July 2007-June 2016.](pone.0219818.g003){#pone.0219818.g003}

Dispensing rates (DRs) {#sec017}
----------------------

When just three periods 2007--2016 were modelled, *Model A* shows the DR for the pre-index period (mean 4.7 years) was 84/100py for acute DDI participants, 75/100py for non-acute DDI, and 47/100py for non-DDI participants ([Table 2](#pone.0219818.t002){ref-type="table"}). For the index period, *Model B* shows the DR for acute DDI participants reached 325/100py, non-acute 108/100py, and 54/100py in non-DDI participants. After the index date (mean 3.7 years), *Model C* shows the DR in acute DDI participants stabilised at 141/100py, over twice that for non-DDI participants.

10.1371/journal.pone.0219818.t002

###### Dispensing rates per 100 person-years, dispensing rate difference and dispensing rate ratio of antibiotics in the periods A) before B) about, and C) after index date.

![](pone.0219818.t002){#pone.0219818.t002g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                               Dispensing rates (95%CI)[\*](#t002fn002){ref-type="table-fn"}   Dispensing rate difference (95%CI)[\*](#t002fn002){ref-type="table-fn"}   Dispensing rate ratio (95%CI)
  ---------------------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------- -------------------------------
  **Model A: from July 2007 to 3 months before index date**\                                                                                                                                                             
  (mean follow-up: 4.7 years)                                                                                                                                                                                            

  Acute DDI                                                                    84 (82 to 86)                                                   37 (35 to 39)                                                             1.79 (1.75 to 1.82)

  Non-Acute DDI                                                                75 (73 to 76)                                                   28 (26 to 29)                                                             1.59 (1.56 to 1.62)

  Non-DDI                                                                      47 (47 to 48)                                                   0                                                                         1.00 (ref.)

  **Model B: for period from 3 months before to 3 months after index date**\                                                                                                                                             
  (mean follow-up: 0.5 years)                                                                                                                                                                                            

  Acute DDI                                                                    325 (317 to 334)                                                271 (263 to 280)                                                          6.04 (5.90 to 6.19)

  Non-Acute DDI                                                                108 (106 to 111)                                                54 (52 to 57)                                                             2.01 (1.97 to 2.06)

  Non-DDI                                                                      54 (53 to 55)                                                   0                                                                         1.00 (ref.)

  **Model C: for period from 3 months after index date to June 2016**\                                                                                                                                                   
  (mean follow-up: 3.7 years)                                                                                                                                                                                            

  Acute DDI                                                                    141 (138 to 145)                                                81 (79 to 84)                                                             2.36 (2.31 to 2.41)

  Non-Acute DDI                                                                99 (97 to 101)                                                  39 (37 to 41)                                                             1.65 (1.63 to 1.68)

  Non-DDI                                                                      60 (59 to 61)                                                   0                                                                         1.00 (ref.)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Notes:

\*Expressed per 100 person-years, and adjusted for year of birth, index year, gender, ethnic group and region

CI = confidence intervals, DDI = residents with diverticular disease of the intestine, non-DDI = matched controls without disease, Index date = date of first diverticular disease admission for DDI and their matched non-DDI participants.

Dispensing rate differences (DRDs) {#sec018}
----------------------------------

In each period, adjusted DRDs were markedly higher in DDI participants than in non-DDI participants ([Table 2](#pone.0219818.t002){ref-type="table"}). Following the index period, the absolute excess in community dispensing rates for acute DDI participants was 81/100py, and for non-acute DDI participants 39/100py, higher than non-DDI counterparts, indicating additional dispensing of 55.8/100py overall (81\*0.41 acute + 39\*0.59 non-acute).

Dispensing rate ratios (DRRs) {#sec019}
-----------------------------

[Table 2](#pone.0219818.t002){ref-type="table"} also shows that acute DDI participants use antibiotics at 1.79 times the rate of non-DDI controls prior to their index event. For years post-index date, dispensing rates for acute DDI are 2.36 times higher, and for non-acute DDI 1.65 times higher; in combination this is more than double their non-DDI counterparts.

For these and the models, differences between DDI and non-DDI groups were significant with p-values \<0.0001. Sensitivity analyses using conditional negative binomial methods yielded similar results.

Discussion {#sec020}
==========

Summary {#sec021}
-------

Routinely-collected data enabled estimates of community-dispensed antibiotic use in virtually a whole population. Following the index admission of DDI, 19% were hospitalised again for DDI, but they continued to used antibiotics well above the "norm" of under 60/100py experienced by their non-DDI peers, indicating a high level of primary care management of those with DDI.

This higher use of antibiotics is for all causes in both DDI groups. People with previous DDI may in general experience chronic conditions more frequently, be more likely to access help for symptoms, request antibiotics more readily, or their general practitioners may prescribe them antibiotics more often. If this were not so, then differences in dispensing could be a useful measure of DDI recurrence which typically measures re-hospitalisations alone.

Our results indicate that primary care-managed true or clinically-suspected recurrence is significant, and could be considered for burden of disease studies. Studies of recurrence that additionally include home-based follow-up also report higher recurrence than when re-admissions only are included.\[[@pone.0219818.ref030]--[@pone.0219818.ref032]\] For example, a multicentre randomised trial reported 38.5% recurrence inside 2 years (with strict diagnostic criteria that may underestimate "true" recurrence),\[[@pone.0219818.ref033]\] a cohort study reported 410 of 1045 (39.2%) experienced a recurrent event,\[[@pone.0219818.ref034]\] and a systematic review showed 43%-86% recurrence\[[@pone.0219818.ref030]\] although the time period may be unspecified.

Several other findings are notable. Firstly, dispensing rates were elevated years before the first hospital DDI diagnosis, suggesting that the index DDI diagnosis may follow prior episode(s) in which abdominal symptoms were suspected to be DDI but not recorded as such until subsequent hospital colonoscopy. Secondly, dispensing rates were extremely high near the index stay. This may represent dispensing for symptoms being treated shortly before the index hospitalisation; immediately post-discharge to complete a course of treatment; a new script to treat non-resolution of symptoms; or to provide "in reserve" supply of antibiotics for use when symptoms arise. None of these reasons, however, explains the ongoing elevated rates observed for years after the index stay.

Strengths and limitations {#sec022}
-------------------------

This study accessed national databases of hospitalisations and dispensing over nine years, with robust p-values. Emergency department records were not accessed, so people presenting to emergency departments with DDI then discharged within three hours may have been misclassified as non-DDI, as may cases treated entirely within primary care, privately or prior to 2000. However with the healthcare system in NZ providing universal cover for its residents, and restrictions on access to antibiotics, admissions and dispensings are unlikely to be importantly impacted by selection bias. The indications for antibiotic dispensing are not collected in the national databases, so we cannot distinguish DDI dispensings from any others. While this could influence the internal validity of our findings, potential imbalance between groups is minimised by matching each DDI participant with 10 non-DDI participants. No adjustment for length of exposure was possible for people absent from NZ during the study period; models employed assume that residents remain in the cohort until death. Any biases introduced because of these limitations would alter only slightly the overall conclusions.

The findings depend upon reasonably accurate hospital coding of DDI diagnoses. We offer no NZ evidence of diagnosis coding quality. Elsewhere, the first three ICD-10 characters coded (K57) reliably record DDI diagnoses, but sub-codes less so,\[[@pone.0219818.ref035], [@pone.0219818.ref036]\] hence our decision not to differentiate e.g. between uncomplicated and complicated DDI in our reporting.

Comparison with existing literature {#sec023}
-----------------------------------

Studies of DDI report recurring pain and other chronic symptoms, anxiety or fear of recurrence, all leading to lower quality of life.\[[@pone.0219818.ref001]--[@pone.0219818.ref003]\] Indeed, the proposal that DDI is a chronic condition\[[@pone.0219818.ref031]\] appears accepted with little debate, yet few studies inform management of patients presenting to primary care with presumed acute DDI.\[[@pone.0219818.ref012]\] We reviewed 14 clinical guidelines published since 2010 (11 using published evidence,\[[@pone.0219818.ref008], [@pone.0219818.ref037]--[@pone.0219818.ref046]\] three based on consensus\[[@pone.0219818.ref047]--[@pone.0219818.ref049]\]). While several recommend that patients who present to hospital with uncomplicated DDI can be managed as outpatients, just three mention primary care: one regarding initial presentations to primary care,\[[@pone.0219818.ref040]\] one regarding referrals to secondary care,\[[@pone.0219818.ref037]\] and one in the context of management of recurrent episodes.\[[@pone.0219818.ref046]\] While it is easy to infer that DDI is almost always managed in hospital, we have shown that recurrent DDI is commonly managed in primary care, with little supporting evidence. We therefore recommend that DDI guidelines should either include all relevant specialist groups---including primary care practitioners---or else clarify the setting(s) for which the guideline is intended.

Implications for research and practice {#sec024}
--------------------------------------

Prior to the current study, we conducted semi-structured interviews with a small sample of volunteers with self-reported ongoing DDI. Their expressed needs were to reduce recurrence, better recognise symptoms, understand familial risk, intervene effectively and inform treatment for other conditions given their DDI (unpublished, details available from corresponding author). Similar needs are apparent also in the USA.\[[@pone.0219818.ref003]\] Evidence about risk factors, triggers, early signs of recurrence, effectiveness of potential alternatives to antibiotic therapy such as self-managed bowel rest, and when antibiotics or dietary modifications are advisable, would all be helpful.

Recognised good practice for people with recurring or chronic conditions is that they are involved with their own care plan.\[[@pone.0219818.ref050], [@pone.0219818.ref051]\] Improved self-management of chronic conditions is proposed as one strategy to slow rapidly rising global demand on health services as a result of population ageing.\[[@pone.0219818.ref052], [@pone.0219818.ref053]\] Modifying primary care management has potential to reduce hospital presentations, recurrence, antibiotic use (important with concerns about increasing antibiotic resistance)\[[@pone.0219818.ref018]\]. Easier access to diagnostic tools (including CT scan and quick point-of-care CRP testing) within primary care to exclude either complicated DDI or acute DDI as a diagnosis,\[[@pone.0219818.ref054]\] and developing and applying better prognostic rules\[[@pone.0219818.ref055]\] have potential in this regard. Results of recent studies in secondary care have led to guidelines increasingly avoiding antibiotics for uncomplicated DDI. Caution is needed before implementing similar advice in primary care, given our findings of widespread use of antibiotics and in the absence of readily available and reliable diagnostic testing (for example CT or CRP testing).\[[@pone.0219818.ref011]\]

Clinical guidance for those managing people with hospital-diagnosed DDI has previously overlooked their markedly higher rates of oral antibiotics use spanning at least several years that suggests DDI has greater impact on subsequent management than previously recognised. Evidence is needed to inform primary care physicians and their patients.
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